Compare Stocks → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APYXNASDAQ:ICUNYSE:ISRNASDAQ:NVNO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPYXApyx Medical$1.32+4.8%$1.74$1.21▼$7.97$45.73M1.09144,978 shs54,670 shsICUSeaStar Medical$0.49+11.4%$0.79$0.16▼$2.28$27.01M-1.185.44 million shs2.20 million shsISRIsoray$0.37$0.19▼$0.45$54.57M1.48290,697 shs145,000 shsNVNOenVVeno Medical$5.50+12.0%$5.54$2.51▼$6.97$73.26M1.17118,275 shs139,226 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPYXApyx Medical-4.55%-8.70%+0.80%-43.50%-56.55%ICUSeaStar Medical+7.60%-34.23%-45.40%-45.72%-79.44%ISRIsoray0.00%0.00%0.00%0.00%0.00%NVNOenVVeno Medical+6.28%-0.20%-13.10%+17.18%+16.90%Putin and other countries have a plan (Ad)Did you catch that bombshell Tucker Carlson interview with Vladimir Putin? It’s not about if you like Tucker or think Putin is the devil or whatever. It's all about the fact that the US dollar might be taking a back seat... and soon. Click to kickstart your journey to survive in the new economyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPYXApyx Medical3.8041 of 5 stars3.54.00.04.20.01.70.6ICUSeaStar MedicalN/AN/AN/AN/AN/AN/AN/AN/AISRIsorayN/AN/AN/AN/AN/AN/AN/AN/ANVNOenVVeno Medical0.1567 of 5 stars0.02.00.00.01.41.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPYXApyx Medical3.00Buy$6.17367.17% UpsideICUSeaStar MedicalN/AN/AN/AN/AISRIsorayN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPYXApyx Medical$52.35M0.87N/AN/A$0.78 per share1.69ICUSeaStar MedicalN/AN/AN/AN/A($0.25) per shareN/AISRIsoray$10.80M0.00N/AN/A$0.43 per share0.00NVNOenVVeno MedicalN/AN/AN/AN/A$3.47 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPYXApyx Medical-$18.71M-$0.54N/AN/AN/A-35.75%-54.90%-28.41%5/9/2024 (Estimated)ICUSeaStar Medical-$26.23M-$1.21N/A∞N/AN/AN/A-741.57%5/20/2024 (Estimated)ISRIsoray-$7.27M-$0.07N/AN/AN/A-115.91%-17.12%-16.15%N/ANVNOenVVeno Medical-$23.52M-$1.92N/AN/AN/AN/A-70.17%-64.68%5/6/2024 (Estimated)Latest APYX, ICU, ISR, and NVNO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023APYXApyx Medical-$0.13-$0.19-$0.06-$0.10$14.40 million$14.66 million2/29/2024Q4 2023NVNOenVVeno MedicalN/A-$0.32-$0.32-$0.32N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPYXApyx MedicalN/AN/AN/AN/AN/AICUSeaStar MedicalN/AN/AN/AN/AN/AISRIsorayN/AN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPYXApyx Medical1.235.524.74ICUSeaStar MedicalN/A0.180.18ISRIsorayN/A14.3813.99NVNOenVVeno MedicalN/A34.2234.23OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPYXApyx Medical55.33%ICUSeaStar Medical1.69%ISRIsoray11.32%NVNOenVVeno Medical34.71%Insider OwnershipCompanyInsider OwnershipAPYXApyx Medical13.10%ICUSeaStar Medical4.50%ISRIsoray2.42%NVNOenVVeno Medical17.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPYXApyx Medical25234.64 million30.11 millionOptionableICUSeaStar Medical955.12 million52.64 millionNot OptionableISRIsorayN/A142.11 million138.67 millionNot OptionableNVNOenVVeno Medical1913.32 million11.05 millionOptionableAPYX, ICU, ISR, and NVNO HeadlinesSourceHeadlineNew Topline Efficacy Data from the enVVeno Medical…pharmiweb.com - April 16 at 1:05 PMNew Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024finance.yahoo.com - April 16 at 1:05 PMenVVeno Medical hires new CCO to guide transitionuk.investing.com - April 11 at 9:42 AMenVVeno Medical Corporation: enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officerfinanznachrichten.de - April 10 at 4:14 AMenVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officerfinance.yahoo.com - April 9 at 12:21 PMenVVeno Medical Corporation (NASDAQ:NVNO) CTO Hamed Alavi Sells 8,334 Sharesinsidertrades.com - March 16 at 10:58 AMNVNO Apr 2024 10.000 callfinance.yahoo.com - March 16 at 2:23 AMenVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunityfinance.yahoo.com - March 15 at 11:16 AMPositive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meetingfinance.yahoo.com - March 6 at 5:49 PMCompanies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growthfinance.yahoo.com - March 3 at 11:28 AMenVVeno Medical Corporation: enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - February 29 at 8:20 PMRecap: enVVeno Medical Q4 Earningsbenzinga.com - February 29 at 8:20 PMenVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - February 29 at 8:20 PMTopline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024finance.yahoo.com - February 20 at 10:08 AMenVVeno Medical Corporation's (NASDAQ:NVNO) Path To Profitabilityfinance.yahoo.com - January 6 at 9:49 AMNVNO Jan 2024 5.000 callca.finance.yahoo.com - December 29 at 4:00 PMenVVeno Medical Corporation: enVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposiumfinanznachrichten.de - December 14 at 12:07 PMenVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposiumfinance.yahoo.com - December 14 at 12:07 PMenVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposiumfinance.yahoo.com - November 16 at 9:45 AMenVVeno Medical Corporation: enVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - October 26 at 8:13 PMenVVeno Medical files to sell 14.71M shares for holdersmsn.com - October 26 at 8:13 PMenVVeno Medical reports Q3 resultsmsn.com - October 26 at 3:10 PMenVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - October 26 at 8:22 AMenVVeno Medical to Participate at the Virtual Investor Ask the CEO Conferencefinance.yahoo.com - October 12 at 1:21 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s Portfolio3 High Dividend Stocks to Replace Lower Savings Yields AheadApril 9, 2024 9:15 AMView 3 High Dividend Stocks to Replace Lower Savings Yields AheadPredicting a Bear Market: 7 Signs and Why it's Tough to DoApril 17, 2024 12:00 PMView Predicting a Bear Market: 7 Signs and Why it's Tough to DoIntuitive Surgical Leads the Robotic Surgery MovementApril 22, 2024 6:10 AMView Intuitive Surgical Leads the Robotic Surgery MovementBuckle Up or Bail Out? The Self-Driving Taxi Market's Risky RideApril 16, 2024 9:45 AMView Buckle Up or Bail Out? The Self-Driving Taxi Market's Risky RideAll Headlines Company DescriptionsApyx MedicalNASDAQ:APYXApyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets in the United States and internationally. It operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). The company offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. Its Helium Plasma Technology products are marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It also develops and manufactures hand pieces for open and laparoscopic procedures; and OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.SeaStar MedicalNASDAQ:ICUSeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. SeaStar Medical Holding Corporation is headquartered in Denver, Colorado.IsorayNYSE:ISRIsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.enVVeno MedicalNASDAQ:NVNOenVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.